从资金流向上来看，当日医疗服务板块主力资金净流出2.28亿元，游资资金净流入1.68亿元，散户资金 净流入5964.42万元。医疗服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，9月16日医疗服务板块较上一交易日上涨0.29%，诚达药业领涨。当日上证指数报收于 3861.87，上涨0.04%。深证成指报收于13063.97，上涨0.45%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301201 | 诚达药业 | 33.32 | 15.25% | 15.71万 | | 5.08亿 | | 002622 | 皓宸医疗 | 4.25 | 10.10% | 99.32万 | | 4.09亿 | | 002172 | 澳洋健康 | 4.73 | 10.00% | 8.75万 | | 4139.70万 | | 688073 | 毕得医药 ...

9月15日，药康生物涨5.16%，截至发稿，报19.35元/股，成交6219.35万元，换手率0.80%，总市值79.34 亿元。 诺安先锋混合A（320003）基金经理为杨谷。 截至发稿，杨谷累计任职时间19年211天，现任基金资产总规模51.33亿元，任职期间最佳基金回报 1033.17%， 任职期间最差基金回报3.03%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，江苏集萃药康生物科技股份有限公司位于江苏省南京市江北新区学府路12号，成立日期2017 年12月29日，上市日期2022年4月25日，公司主营业务涉及实验动物小鼠模型的研发、生产、销售及相 关技术服务。主营业务收入构成为：商品化小鼠模型销售55.36%，功能药效23.46%，定制繁育 11.32%，模型创制7.06%，代理进出口及其他2.70%，其他(补充)0.09%。 从药康生物十大流通股东角度 数据显示，诺安基金旗下1只基金位居药康生物十大流通股东。诺安先锋混合A（ ...

华泰联合证券有限责任公司 关于江苏集萃药康生物科技股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：江苏集萃药康生物科技股 | | --- | --- | | | 份有限公司 | | 保荐代表人姓名：季李华 | 联系电话：010-56839300 | | 保荐代表人姓名：李皓 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐人"）作为江苏集萃药康生物科技股份有限公 司（以下简称"药康生物"、"公司"或"发行人"）首次公开发行股票的保荐 人，对药康生物进行持续督导，并出具本 2025 年半年度（以下简称"报告期"） 持续督导跟踪报告： 一、保荐人和保荐代表人发现的问题及整改情况 保荐人核查发现，由于受内外部因素影响，报告期内公司募集资金投资项目 实施进度存在晚于预期情形。 公司已于2022年年度报告、2023年半年度报告、2023年年度报告、2024年半 年度报告、2024年年度报告、2 ...

强化海外一站式服务，共建全球客户生态 近日，江苏集萃药康生物科技股份有限公司（以下简称"药康生物"）与上海益诺思生物技术股份有限公 司（以下简称"益诺思"）正式签署战略合作协议。 药康生物作为国内模式动物领域的领军企业，深耕非临床安全性评价上游模型开发，也在致癌评价方向 积累多年小鼠模型应用数据，该模型对阳性致癌物的自发肿瘤响应率极高，益诺思作为国内头部的、符 合药物非临床研究质量管理规范（GLP）的非临床安全性评价机构，拥有完善的毒理学研究资质及国际 化服务能力，双方基于产业链协同需求，拟在模型开发—安评应用—海外拓展领域展开深度合作，共同 推动我国生物医药研发产业链的自主可控与全球化布局。 联合推进国产非临床致癌评价小鼠模型的规模化应用 药康生物依托自主研发的小鼠模型（已验证对阳性致癌物的高响应率及稳定性），益诺思依托在非临床 安全性评价领域的完善资质及丰富经验，双方深度合作，共同完成该模型在非临床致癌性研究中的标准 化应用验证，推动相关模型成为国内符合GLP规范的、行业领先的商业化致癌评价模型。 双方将共享模型在致癌评价中的实验数据（包括肿瘤发生率、潜伏期、组织病理学特征等），依托益诺 思符合GLP标准 ...

Group 1 - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (Yaokang Bio) and Shanghai Yinos Biotech Co., Ltd. (Yinos) have signed a strategic cooperation agreement to enhance collaboration in the field of non-clinical safety evaluation and model development [1] - Yaokang Bio is a leading company in the domestic model animal sector, focusing on non-clinical safety evaluation and has accumulated extensive data on mouse models for carcinogenic evaluation, which exhibit a high response rate to positive carcinogens [1][2] - Yinos is a top-tier non-clinical safety evaluation institution in China, compliant with Good Laboratory Practice (GLP) standards, possessing comprehensive toxicology research qualifications and international service capabilities [1][2] Group 2 - The collaboration aims to standardize the application of domestically developed non-clinical carcinogenic evaluation mouse models, enhancing their recognition in the industry and promoting their commercialization [2] - Both companies will share experimental data related to tumor incidence, latency, and histopathological characteristics to improve the model's industry acceptance [2] - The partnership will facilitate the large-scale application of these models in innovative drug development enterprises [2] Group 3 - Yaokang Bio will leverage its strengths in model construction and non-GLP pharmacology and toxicology evaluation to provide preliminary drug activity screening and mechanism research services for overseas clients [3] - Yinos will utilize its internationally certified GLP toxicology evaluation qualifications to conduct subsequent pharmacokinetic and safety evaluations [3] - The collaboration aims to create a comprehensive overseas customer service loop, integrating efficacy, pharmacokinetics, and safety evaluation [3] Group 4 - The partnership combines the resource advantages of both companies, facilitating the entry of Yaokang Bio's mouse models into the evaluation supply chain [4] - The collaboration will target key domestic and international clients, establishing a benchmark cooperation model for the biopharmaceutical industry [4] - A global service network will be developed, covering major pharmaceutical markets, promoting the "Chinese model animals + Chinese evaluation services" paradigm [4]

证券日报网讯9月2日晚间，药康生物发布公告称，截至2025年8月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式累计回购公司股份1，492，387股，占公司总股本410，000，000股的比例为 0.3640%。 ...

Summary of Key Points - The company, Yaokang Biotechnology (688046.SH), announced a share buyback program, having repurchased a total of 1.4924 million shares, which represents 0.3640% of its total share capital [1] - The highest price paid for the repurchased shares was 17.76 RMB per share, while the lowest price was 10.52 RMB per share [1] - The total amount spent on the share buyback was 21.1377 million RMB, excluding transaction fees such as stamp duty and commissions [1]

证券代码：688046 证券简称：药康生物 公告编号：2025-063 江苏集萃药康生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/31 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 10 | 10 | 29 | 日~2025 | 年 | 月 | 28 | 日 | | 预计回购金额 | 2,200万元~4,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 1,492,387股 | | | | | | | | | 累计已回购 ...

Core Insights - Jiangsu Jicui Pharmaceutical Technology Co., Ltd. (药康生物) has shown a mixed performance in its financial metrics, with a revenue increase but a decline in net profit [2][3] - The company has a significant presence in the market for laboratory mouse models, with a diverse revenue stream from various business segments [1] Financial Performance - For the first half of 2025, the company reported a revenue of 375 million yuan, representing a year-on-year growth of 10.11% [2] - The net profit attributable to shareholders was approximately 70.91 million yuan, reflecting a year-on-year decrease of 7.12% [2] Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 23.68% to 7,213, with an average of 56,841 circulating shares per shareholder, up by 62.56% [2] - On September 1, 2023, the company's stock price increased by 1.31%, with a trading volume of approximately 59.66 million yuan [1] Financing and Margin Trading - On September 1, 2023, the company had a net financing outflow of 1.61 million yuan, with a total financing balance of 112 million yuan, accounting for 1.54% of its market capitalization [1] - The margin trading data indicates a high financing balance, while the short selling activity remains relatively low, with a short selling balance of 196,300 yuan [1] Dividend Distribution - Since its A-share listing, the company has distributed a total of 139 million yuan in dividends [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include China Europe Medical Health Mixed Fund and others, with some institutions reducing their holdings [3]

Core Insights - The Jiangsu provincial government is focusing on the development of the biopharmaceutical industry, emphasizing the implementation of the recently approved open innovation development plan for the entire biopharmaceutical industry chain in the Jiangsu Free Trade Zone [1][2] - The government aims to enhance the integration of technological and industrial innovation, leveraging policy advantages to significantly improve the level of openness and accelerate breakthroughs in core technologies [1][3] Industry Development - The biopharmaceutical industry is identified as a key advantageous sector for Jiangsu, with a focus on creating a world-class biopharmaceutical cluster and enhancing international competitiveness [1][2] - The government encourages companies to focus on niche areas and collaborate closely with pharmaceutical companies, universities, and clinical institutions to drive new drug development and technology transfer [2][3] Policy Implementation - The provincial government is committed to ensuring that policy benefits are effectively communicated to enterprises, aiming to create replicable and scalable success stories that can drive innovation and spillover effects in the biopharmaceutical sector [3]